Advanced clinical symptoms of the antihangover compound HK-GCM-H01 in healthy Koreans.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY Translational and Clinical Pharmacology Pub Date : 2024-09-01 Epub Date: 2024-09-23 DOI:10.12793/tcp.2024.32.e11
Ye Lim Jang, Min Kyu Park
{"title":"Advanced clinical symptoms of the antihangover compound HK-GCM-H01 in healthy Koreans.","authors":"Ye Lim Jang, Min Kyu Park","doi":"10.12793/tcp.2024.32.e11","DOIUrl":null,"url":null,"abstract":"<p><p>A hangover is a combination of negative mental and physical symptoms, such as headache, diarrhea, and loss of appetite, that occur after alcohol consumption and can vary depending on individual genetic and environmental factors. To quickly relieve these hangover symptoms, a new hangover relief compound called HK-GCM-H01 has been developed. This compound, HK-GCM-H01, consists of fermented rice germ extracts, yeast extract mixtures, cili extract powder, and concentrated nipafam powder, all of which are known to relieve hangover symptoms. The safety and clinical symptoms of HK-GCM-H01 were evaluated, along with the pharmacokinetic properties of alcohol and acetaldehyde after its administration. This study was conducted on 50 healthy Korean men using a randomized, double-blind, placebo-controlled, single-intake, crossover design. To evaluate clinical symptoms, Acute Hangover Scale and Alcohol Hangover Severity Scale were used, and the pharmacokinetic evaluation parameters included the maximum plasma concentration, the time to peak plasma concentration, the terminal half-life, and the area under the plasma concentration-time curve from X hours to Y hours. A significant reduction in clinical symptoms was observed after alcohol consumption in the group that consumed HK-GCM-H01 with added hangover relief compound, as was a significant decrease in blood exposure to acetaldehyde compared to the placebo group. There were no adverse events or significant changes in liver function indicators reported during the safety evaluation. These findings indicate that HK-GCM-H01 is safe and significantly reduces plasma concentrations of acetaldehyde, the main cause of hangover, suggesting that it improves hangover symptoms.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":"32 3","pages":"137-149"},"PeriodicalIF":1.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458339/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational and Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12793/tcp.2024.32.e11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

A hangover is a combination of negative mental and physical symptoms, such as headache, diarrhea, and loss of appetite, that occur after alcohol consumption and can vary depending on individual genetic and environmental factors. To quickly relieve these hangover symptoms, a new hangover relief compound called HK-GCM-H01 has been developed. This compound, HK-GCM-H01, consists of fermented rice germ extracts, yeast extract mixtures, cili extract powder, and concentrated nipafam powder, all of which are known to relieve hangover symptoms. The safety and clinical symptoms of HK-GCM-H01 were evaluated, along with the pharmacokinetic properties of alcohol and acetaldehyde after its administration. This study was conducted on 50 healthy Korean men using a randomized, double-blind, placebo-controlled, single-intake, crossover design. To evaluate clinical symptoms, Acute Hangover Scale and Alcohol Hangover Severity Scale were used, and the pharmacokinetic evaluation parameters included the maximum plasma concentration, the time to peak plasma concentration, the terminal half-life, and the area under the plasma concentration-time curve from X hours to Y hours. A significant reduction in clinical symptoms was observed after alcohol consumption in the group that consumed HK-GCM-H01 with added hangover relief compound, as was a significant decrease in blood exposure to acetaldehyde compared to the placebo group. There were no adverse events or significant changes in liver function indicators reported during the safety evaluation. These findings indicate that HK-GCM-H01 is safe and significantly reduces plasma concentrations of acetaldehyde, the main cause of hangover, suggesting that it improves hangover symptoms.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
健康韩国人服用抗宿醉化合物 HK-GCM-H01 后出现的晚期临床症状。
宿醉是饮酒后出现的头痛、腹泻和食欲不振等精神和身体负面症状的综合表现,因个人遗传和环境因素而异。为了快速缓解这些宿醉症状,一种名为 HK-GCM-H01 的新型宿醉缓解化合物应运而生。HK-GCM-H01 复方制剂由发酵的大米胚芽提取物、酵母提取物混合物、纤毛提取物粉末和浓缩尼泊金粉末组成,所有这些物质都能缓解宿醉症状。本研究评估了 HK-GCM-H01 的安全性和临床症状,以及服用后酒精和乙醛的药代动力学特性。这项研究以 50 名健康的韩国男性为对象,采用随机、双盲、安慰剂对照、单次服用、交叉设计。评估临床症状时使用了急性宿醉量表和酒精宿醉严重程度量表,药代动力学评估参数包括最大血浆浓度、达到血浆浓度峰值的时间、终末半衰期以及从 X 小时到 Y 小时的血浆浓度-时间曲线下面积。与安慰剂组相比,服用添加了宿醉缓解化合物的 HK-GCM-H01 组在饮酒后临床症状明显减轻,血液中乙醛的暴露量也明显减少。在安全性评估期间,未报告任何不良事件或肝功能指标的重大变化。这些研究结果表明,HK-GCM-H01 是安全的,它能显著降低宿醉的主要原因--乙醛的血浆浓度,从而改善宿醉症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Translational and Clinical Pharmacology
Translational and Clinical Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.60
自引率
11.10%
发文量
17
期刊介绍: Translational and Clinical Pharmacology (Transl Clin Pharmacol, TCP) is the official journal of the Korean Society for Clinical Pharmacology and Therapeutics (KSCPT). TCP is an interdisciplinary journal devoted to the dissemination of knowledge relating to all aspects of translational and clinical pharmacology. The categories for publication include pharmacokinetics (PK) and drug disposition, drug metabolism, pharmacodynamics (PD), clinical trials and design issues, pharmacogenomics and pharmacogenetics, pharmacometrics, pharmacoepidemiology, pharmacovigilence, and human pharmacology. Studies involving animal models, pharmacological characterization, and clinical trials are appropriate for consideration.
期刊最新文献
Analyzing collaborations in clinical trials in Korea using association rule mining. Cardiotoxicity evaluation of two-drug fixed-dose combination therapy under CiPA: a computational study. Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic. PMDA initiatives to enhance drug development via multi-regional clinical trials. Research on unintroduced new drugs in South Korea from 2011 to 2020: approaches to prioritization and strategy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1